Ansbert Gadicke
Founder at MPM BioImpact, Inc
Network origin in Ansbert Gadicke first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
110
| Private Company | Investment Managers | 110 |
| Holding Company | Biotechnology | 42 | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.
41
| Private Company | Miscellaneous Commercial Services | 41 |
| Subsidiary | Pharmaceuticals: Major | 29 | |
| Public Company | Pharmaceuticals: Major | 23 | |
| Subsidiary | Pharmaceuticals: Major | 23 | |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.
19
| Subsidiary | Pharmaceuticals: Other | 19 |
| Public Company | Biotechnology | 16 | |
| Subsidiary | Pharmaceuticals: Major | 15 | |
PharmAthene, Inc. /Old/
 PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
14
| Extinct | Biotechnology | 14 |
| Public Company | Biotechnology | 14 | |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.
13
| Public Company | Biotechnology | 13 |
| Public Company | Biotechnology | 13 | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts.
12
| Holding Company | Investment Managers | 12 |
| Public Company | Biotechnology | 11 | |
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance Founded in 1997 by Ansbert Gadicke and Luke Evnin, MPM BioEquities Adviser LLC is a hedge fund manager located in South San Francisco, California with an additional office in Boston. The firm is a subsidiary of MPM Capital LP, a private equity firm.
10
| Extinct | Investment Managers | 10 |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.
8
| Holding Company | Biotechnology | 8 |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.
7
| Holding Company | Biotechnology | 7 |
Mindset BioPharmaceuticals Ltd.
 Mindset BioPharmaceuticals Ltd. Medical/Nursing ServicesHealth Services Mindset BioPharmaceuticals Ltd. develops disease modifying therapies. It specializes in molecular neuropharmacology, behavioral science, clinical neurology, drug delivery, and biopharmaceutical development. The company was founded by Daniel G. Chain in February 1997 and is headquartered in Jerusalem, Israel.
6
| Private Company | Medical/Nursing Services | 6 |
Mitobridge, Inc.
 Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA.
4
| Subsidiary | Biotechnology | 4 |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million.
2
| Subsidiary | Biotechnology | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Ansbert Gadicke via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal President Corporate Officer/Principal Corporate Officer/Principal | |
| CELGENE | Biotechnology | President Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Sales & Marketing Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer Compliance Officer | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member | |
UBS Securities LLC
 UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Managers | Analyst-Equity Analyst-Equity Corporate Officer/Principal | |
| Bayer Pharmaceuticals Corp. | Director of Finance/CFO President | ||
| ONCOSEC MEDICAL INCORPORATED | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Masters Business Admin Doctorate Degree Undergraduate Degree Doctorate Degree | |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
| Boston University | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree | |
| BLUEBIRD BIO, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Consultant / Advisor Corporate Officer/Principal | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Chief Executive Officer Private Equity Analyst | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| Brandeis University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| University College London | College/University | Doctorate Degree Undergraduate Degree | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| ONCORUS, INC. | Biotechnology | Chairman Chief Executive Officer Director/Board Member | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder Director/Board Member | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer Director of Finance/CFO Director of Finance/CFO | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder Investor Relations Contact Director/Board Member Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Director/Board Member Chairman Director/Board Member | |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member Chairman Chief Executive Officer | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director of Finance/CFO Director/Board Member Chairman | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Chief Executive Officer Corporate Officer/Principal | |
LifeEDIT Therapeutics, Inc.
 LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Director/Board Member | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Director/Board Member Director/Board Member Founder | |
| ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Chief Operating Officer Director/Board Member Corporate Officer/Principal |
Statistics
International
| United States | 42 |
| United Kingdom | 5 |
| Germany | 2 |
| Switzerland | 2 |
| Israel | 2 |
Sectoral
| Health Technology | 26 |
| Consumer Services | 12 |
| Finance | 7 |
| Health Services | 5 |
| Commercial Services | 4 |
Operational
| Director/Board Member | 572 |
| Corporate Officer/Principal | 244 |
| Independent Dir/Board Member | 170 |
| Chief Executive Officer | 118 |
| Founder | 109 |
Most connected contacts
| Insiders | |
|---|---|
| Luke Evnin | 42 |
| Derace L. Schaffer | 37 |
| Kurt von Emster | 34 |
| Thomas Ebeling | 33 |
| Dieter Weinand | 32 |
| Michael Wyzga | 31 |
| Richard H. Aldrich | 31 |
| Edward Hurwitz | 27 |
| Mitchell Finer | 26 |
| Briggs Morrison | 26 |
| Jeffrey Bornstein | 26 |
| Robert Williamson | 25 |
| Robert M. Forrester | 25 |
| Michael Kauffman | 24 |
| Anthony Adam Rosenberg | 23 |
- Stock Market
- Insiders
- Ansbert Gadicke
- Company connections
